Key points are not available for this paper at this time.
Abstract Background: PAM50, a 50-gene signature, classifies breast cancers into one of five subtypes (basal, luminal A, luminal B, HER2-enriched, and normal-like), revealing information about underlying tumor biology, and has emerged as a key prognostic indicator influencing treatment decisions. There is growing interest in bridging the gap between expression-based metrics and histopathology, where immunohistochemistry (IHC) and sequencing-based approaches have been proposed for this purpose. However, hematoxylin and eosin (H 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO3-07-04.
Guramare et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: